丹参酮ⅡA磺酸钠联合厄贝沙坦对高血压合并肾损伤患者尿NAG、β_(2)-MG、血清PICP及PCX水平的影响  

Effects of tanshinone ⅡA sodium sulfonate injection combined with Irbesartan on urinary NAG, β-MG,serumPICP and PCX levels in patients with hypertensive complicated by kidney injury

作　　者：史晗冰[1] 李跃飞[1] 徐靖华[1] 李圣[1] 刘建光[1] 金巍[1] Shi Hanbing;Li Yuefei;Xu Jinghua;Li Sheng;Liu Jianguang;Jin Wei(Department of Emergency Medicine,The Fourth Hospital Affiliated to Liaoning University of Traditional Chinese Medicine,Shenyang 110101,China)

机构地区：[1]辽宁中医药大学附属第四医院急诊科,沈阳110101

出　　处：《保健医学研究与实践》2020年第6期45-49,共5页Health Medicine Research and Practice

基　　金：辽宁省省直医院改革重点临床科室诊疗能力建设项目(辽财指社〔2015〕458号)。

摘　　要：目的探讨丹参酮ⅡA磺酸钠联合厄贝沙坦对高血压合并肾损伤患者尿N-乙酰-β-D-葡萄糖苷酶(NAG)、β_(2)-微球蛋白(β_(2)-MG)、血清I型前胶原羧基末端前肽(PICP)及足细胞标记蛋白(PCX)水平的影响。方法选取2017年1月—2019年6月沈阳市某医院收治的94例高血压合并肾损伤患者为研究对象,采用随机数字表法将患者分为观察组和对照组,每组47例。对照组患者给予厄贝沙坦(150 mg/d)口服治疗,观察组患者在对照组治疗基础上给予丹参酮ⅡA磺酸钠注射液(50 mg/d)静脉推注,共治疗8周。比较2组患者治疗前后血压、PICP、PCX水平,血清尿素氮和肌酐水平,尿NAG、β_(2)-MG和尿微量白蛋白(m ALB)水平,同时比较2组患者不良反应发生情况。结果治疗前,2组患者收缩压、舒张压、尿素氮、肌酐、血清PICP、PCX水平、尿m ALB、NAG和β_(2)-MG水平比较,差异均无统计学意义(P>0.05)。治疗后,2组患者收缩压、舒张压、尿素氮、肌酐、血清PICP、PCX、尿m ALB、NAG和β_(2)-MG水平均低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。对照组患者在治疗期间共发生不良反应8例,不良反应发生率为17.02%;观察组患者在治疗期间共发生不良反应4例,不良反应发生率为8.51%;2组不良反应发生率比较,差异无统计学意义(χ^(2)=1.528,P=0.216)。结论丹参酮ⅡA磺酸钠联合厄贝沙坦可有效降低高血压合并肾损伤患者的血压、血清及尿液中肾损伤标志物水平,改善高血压合并肾损伤患者的肾功能,且不良反应少,值得临床推广应用。Objective To investigate the effects of tanshinoneⅡA sulfonate sodium injection on the urinary N-ace-tyl-β-D-glucosidase(NAG),β_(2)-microglobulin(β_(2)-MG),serum procollagen type Ⅰ carboxy-terminal propeptide(PICP),and podocyte marker protein podocalyxin(PCX)levels in patients with hypertensive complicatedby kid-ney injury.Methods Ninety-four patients with hypertension complicated by kidney injury admitted to a hospital in Shenyang from January 2017 to June 2019 were selected for the study,and the patients were divided into ob-servation and control groups using the randomized grouping method,with 47 cases in each group.Patients in the control group were given irbesartan(150 mg/d)orally,and patients in the observation group were given tanshi-noneⅡA sulfonate sodium injection(50 mg/d)intravenously on the basis of the treatment in the control group for a total of 8 weeks.The blood pressure,serum PICP and PCX levels,serum urea nitrogen and creatinine lev-els,urinary NAG,β_(2)-MG,and microalbumin(m ALB)levels of the two groups were compared before and after treatment,and the occurrence of adverse reactions was compared between the two groups.Results Before treat-ment,there were no statistically significant differences in systolic and diastolic blood pressure,serum urea nitro-gen and creatinine levels,serum PICP and PCX levels,and serum urinary m ALB,NAG,andβ_(2)-MG levels be-tween the two groups(P>0.05).After treatment,the systolic and diastolic blood pressure,serum urea nitro-gen and creatinine levels,serum PICP and PCX levels,serum urinary m ALB,NAG,andβ_(2)-MG levels were sig-nificantly lower than those before treatment in both groups,and those in the observation group were significantly lower than the control group(P<0.05).In the control group,8 cases of adverse reactions occurred during the treatment,and the incidence of adverse reactions was 17.02%;in the observation group,4 cases of adverse reac-tions occurred during the treatment,and the incidence of adverse reactions was 8.51%;the incidence of adv

关 键 词：丹参酮ⅡA磺酸钠 高血压 肾损伤 肾小球 肾小管 肾纤维化 

分 类 号：R544.1[医药卫生—心血管疾病]